Form 4: Phathom CFO Receives Significant Equity Awards

Phathom Pharmaceuticals' Chief Financial Officer, Sanjeev Narula, was granted 82,715 restricted stock units and options for 42,848 shares of common stock.

Summary

• Sanjeev Narula, Chief Financial & Business Officer of Phathom Pharmaceuticals, Inc. (PHAT), reported an acquisition of equity securities.
• On January 2, 2026, Narula was granted 82,715 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of common stock of the Issuer.
• These RSUs will vest in three equal annual installments, with 1/3 vesting on each of the first three anniversaries of January 2, 2026, subject to continued service.
• Following this transaction, Narula beneficially owns 226,715 shares of common stock.
• Additionally, on January 2, 2026, Narula was granted stock options to purchase 42,848 shares of common stock at an exercise price of $15.71 per share.
• These stock options have an expiration date of January 1, 2036.
• The options vest monthly, with 1/48th of the total number of shares vesting each month following January 2, 2026, subject to continued service.
• Following this transaction, Narula beneficially owns 42,848 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a key executive, which is generally a neutral to slightly positive event as it aligns management incentives with shareholder interests. It does not contain information about company performance or significant strategic shifts.

Positives

• The grant of restricted stock units and stock options aligns the Chief Financial & Business Officer's interests with those of shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice to attract and retain key executives.

Negatives

• No negative aspects are directly discernible from this routine insider transaction filing.

Risks

• The value of the granted equity awards is subject to the future performance of Phathom Pharmaceuticals' common stock.
• Vesting of the awards is contingent upon the reporting person's continued service to the company.

Future Outlook

The equity grants, with their multi-year vesting schedules, indicate an expectation of continued service from the Chief Financial & Business Officer and a long-term commitment to the company's performance.

Industry Context

Equity grants, including RSUs and stock options, are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries, designed to incentivize long-term value creation and retain key talent.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options as part of executive compensation is a common practice across the pharmaceutical and biotech sectors, aligning with global benchmarks for incentivizing leadership.
• Multi-year vesting schedules (e.g., 3-year for RSUs, 4-year for options) are typical for executive equity awards, comparable to practices at companies like Pfizer, Merck, or smaller biotech firms, ensuring long-term retention and performance alignment.

Stakeholder Impact

• Shareholders: The equity grants aim to align the Chief Financial & Business Officer's long-term interests with those of shareholders, potentially leading to improved company performance.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs.

Next Steps

• Continued service of Sanjeev Narula to trigger vesting of RSUs and stock options.
• Vesting of 1/3 of RSUs on each of the first three anniversaries of January 2, 2026.
• Monthly vesting of 1/48th of stock options following January 2, 2026.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Sanjeev Narula, Form 4, Restricted Stock Units, RSU, Stock Options, Equity Grant, Insider Transaction, Executive Compensation